- Home
- ANAB vs LEGH Comparison
ANAB vs LEGH Comparison
Compare ANAB & LEGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- LEGH
- Stock Information
- Founded
- ANAB 2005
- LEGH 2005
- Country
- ANAB United States
- LEGH United States
- Employees
- ANAB N/A
- LEGH N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- LEGH Homebuilding
- Sector
- ANAB Health Care
- LEGH Consumer Discretionary
- Exchange
- ANAB Nasdaq
- LEGH Nasdaq
- Market Cap
- ANAB 630.2M
- LEGH 646.4M
- IPO Year
- ANAB 2017
- LEGH 2018
- Fundamental
- Price
- ANAB $21.08
- LEGH $27.88
- Analyst Decision
- ANAB Buy
- LEGH Strong Buy
- Analyst Count
- ANAB 10
- LEGH 1
- Target Price
- ANAB $48.00
- LEGH $29.00
- AVG Volume (30 Days)
- ANAB 515.2K
- LEGH 75.0K
- Earning Date
- ANAB 11-04-2025
- LEGH 11-11-2025
- Dividend Yield
- ANAB N/A
- LEGH N/A
- EPS Growth
- ANAB N/A
- LEGH 2.38
- EPS
- ANAB N/A
- LEGH 2.23
- Revenue
- ANAB $123,164,000.00
- LEGH $184,284,000.00
- Revenue This Year
- ANAB $11.40
- LEGH $0.57
- Revenue Next Year
- ANAB $8.17
- LEGH $8.92
- P/E Ratio
- ANAB N/A
- LEGH $12.34
- Revenue Growth
- ANAB 304.17
- LEGH 8.79
- 52 Week Low
- ANAB $12.21
- LEGH $21.58
- 52 Week High
- ANAB $39.50
- LEGH $29.45
- Technical
- Relative Strength Index (RSI)
- ANAB 47.97
- LEGH 60.34
- Support Level
- ANAB $17.11
- LEGH $26.96
- Resistance Level
- ANAB $24.07
- LEGH $28.35
- Average True Range (ATR)
- ANAB 1.49
- LEGH 0.78
- MACD
- ANAB -0.03
- LEGH -0.18
- Stochastic Oscillator
- ANAB 57.03
- LEGH 42.70
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.